US FDA Approves New Treatment for Myasthenia Gravis

The U.S. Food and Drug Administration today approved Vyvgart (efgartigimod) for the treatment of generalized myasthenia gravis (gMG) in adults who test positive for the anti-acetylcholine receptor (AChR) antibody. - eTurboNews | Trends | Travel News
http://dlvr.it/SFbsd6